Ga‐68 EDTA aerosols in evaluation of inhaled‐particle deposition and clearance of obstructive pulmonary diseases: A pilot prospective study compared with Galligas

Shao‐Ting Wang; Cheng Bao; Qingxing Liu; Tengyue Zhang; Yanli Yang; Xinlun Tian; Zhaohui Zhu; Kai‐Feng Xu

doi:10.1111/eci.13620

journal article Open Access Jun 02, 2021

Ga‐68 EDTA aerosols in evaluation of inhaled‐particle deposition and clearance of obstructive pulmonary diseases: A pilot prospective study compared with Galligas

Shao‐Ting Wang

Cheng Bao Qingxing Liu Tengyue Zhang

Yanli Yang

Xinlun Tian Zhaohui Zhu

Kai‐Feng Xu

European Journal of Clinical Investigation Vol. 51 No. 12 · Wiley

View at Publisher Save 10.1111/eci.13620

Abstract

AbstractPurpose68‐gallium (Ga‐68) ethylenediaminetetraacetic acid (EDTA) aerosols and Galligas were compared in evaluation of inhaled‐particle deposition and clearance in volunteers with or without obstructive pulmonary diseases.MethodsNonsmoking healthy volunteers, healthy smokers, asthma patients and patients with chronic obstructive pulmonary disease (COPD) were recruited to undergo the dynamic lung ventilation positron emission tomography/computerized tomography (PET/CT) scans within two consecutive days. The inhaled particles were Ga‐68–labelled carbon nanoparticles (Galligas, 30‐60 nm in size) and Ga‐68–labelled EDTA aerosols (1‐2 μm in size), respectively. The volunteers’ lung function parameters were measured for comparison.ResultsCentral deposition and inhomogeneity of both tracers were negatively correlated with lung function parameters, including the ratio of forced expiratory volume at 1 second to forced vital capacity (FEV1/FVC). The central or hilum deposition of Galligas, but not 68‐gallium (Ga‐68) EDTA, was negatively correlated with the maximal expiratory flow at 25%, 50% and 75% of the forced vital capacity. Compared with Galligas, Ga‐68 EDTA aerosols were more concentrated in the central region in all groups except for the healthy nonsmokers. Ventilation inhomogeneity was more evident when using Ga‐68 EDTA aerosols, especially in patients with COPD and asthma patients. In the healthy smokers, the central region accumulated more Ga‐68 EDTA at 30 minutes after inhalation than immediately after inhalation. Ga‐68 EDTA cleared faster in lungs than Galligas.ConclusionsBoth Galligas and Ga‐68 EDTA aerosols can be used for PET/CT lung ventilation scan. However, Ga‐68 EDTA aerosols showed more advantages in diagnosis and evaluation of obstructive airway diseases by revealing the inhaled‐particle deposition and clearance.

Topics

No keywords indexed for this article. Browse by subject →

References

27

[1]

10.1080/019131200750060014

[2]

10.1080/089583700750019530

[3]

10.1007/s11356-019-04618-z

[4]

10.1097/ede.0000000000000264

[5]

10.1021/es301948k

[6]

10.1080/08958378.2018.1545810

[7]

10.1002/cnm.3215

[8]

10.2967/jnumed.111.093344

[9]

10.1164/ajrccm/144.5.1202

[10]

10.3390/ijerph120100841

[11]

Global strategy for asthma management and prevention

[12]

Global Strategy for the Diagnosis (2017)

[13]

10.1111/j.1365-2362.2009.02234.x

[14]

10.1007/978-3-642-27994-2_22

[15]

Fiji: an open-source platform for biological-image analysis

Johannes Schindelin, Ignacio Arganda-Carreras, Erwin Frise et al.

Nature Methods 10.1038/nmeth.2019

[16]

10.1007/s00134-009-1589-y

[17]

10.1093/bioinformatics/btw413

[18]

10.3109/08958371003713745

[19]

10.1007/s00259-009-1304-9

[20]

10.1164/rccm.200410-1414oc

[21]

10.1053/j.semnuclmed.2018.10.013

[22]

10.1136/thx.41.7.519

[23]

10.1016/j.tiv.2016.11.009

[24]

10.1089/089426802320282301

[25]

10.1089/jamp.2010.0845

[26]

10.1111/j.1440-1843.2010.01853.x

[27]

Pellegrino R "Regional expiratory flow limitation studied with Technegas in asthma" J Appl Physiol (1985)

Metrics

1

Citations

27

References

Details

Published: Jun 02, 2021
Vol/Issue: 51(12)
License: View

Authors

S

Shao‐Ting Wang

Department of Pulmonary and Critical Care Medicine State Key Laboratory of Complex Severe and Rare Diseases Peking Union Medical College Hospital Chinese Academy of Medical Sciences Peking Union Medical College Beijing China

C

Cheng Bao

Department of Pulmonary and Critical Care Medicine State Key Laboratory of Complex Severe and Rare Diseases Peking Union Medical College Hospital Chinese Academy of Medical Sciences Peking Union Medical College Beijing China; Department of Pulmonary and Critical Care Medicine Center of Respiratory Medicine China‐Japan Friendship Hospital Beijing China

Q

Qingxing Liu

Department of Nuclear Medicine State Key Laboratory of Complex Severe and Rare Diseases Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine Peking Union Medical College Hospital Chinese Academy of Medical Sciences Peking Union Medical College Beijing China

T

Tengyue Zhang

Department of Pulmonary and Critical Care Medicine State Key Laboratory of Complex Severe and Rare Diseases Peking Union Medical College Hospital Chinese Academy of Medical Sciences Peking Union Medical College Beijing China

Y

Yanli Yang

Department of Pulmonary and Critical Care Medicine State Key Laboratory of Complex Severe and Rare Diseases Peking Union Medical College Hospital Chinese Academy of Medical Sciences Peking Union Medical College Beijing China

X

Xinlun Tian

Department of Pulmonary and Critical Care Medicine State Key Laboratory of Complex Severe and Rare Diseases Peking Union Medical College Hospital Chinese Academy of Medical Sciences Peking Union Medical College Beijing China

Z

Zhaohui Zhu

Department of Nuclear Medicine State Key Laboratory of Complex Severe and Rare Diseases Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine Peking Union Medical College Hospital Chinese Academy of Medical Sciences Peking Union Medical College Beijing China

K

Kai‐Feng Xu

Department of Pulmonary and Critical Care Medicine State Key Laboratory of Complex Severe and Rare Diseases Peking Union Medical College Hospital Chinese Academy of Medical Sciences Peking Union Medical College Beijing China

Funding

National Natural Science Foundation of China Award: 81871392

National Key Research and Development Program of China Award: 2015CB553402

Cite This Article

Shao‐Ting Wang, Cheng Bao, Qingxing Liu, et al. (2021). Ga‐68 EDTA aerosols in evaluation of inhaled‐particle deposition and clearance of obstructive pulmonary diseases: A pilot prospective study compared with Galligas. European Journal of Clinical Investigation, 51(12). https://doi.org/10.1111/eci.13620

Ga‐68 EDTA aerosols in evaluation of inhaled‐particle deposition and clearance of obstructive pulmonary diseases: A pilot prospective study compared with Galligas

You May Also Like